Daniel Tandel Chang
University of Michigan · 519 works · 13,895 citations · h-index 62
Top works
- Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
- Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas
- Phase 2 multi‐institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma
- Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features
- A Systemic Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy
- Single-Fraction Stereotactic Body Radiation Therapy and Sequential Gemcitabine for the Treatment of Locally Advanced Pancreatic Cancer
- NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017
- Stereotactic body radiotherapy for colorectal liver metastases
- Safety and Efficacy of Percutaneous Fiducial Marker Implantation for Image-guided Radiation Therapy
- A Dosimetric Model of Duodenal Toxicity After Stereotactic Body Radiotherapy for Pancreatic Cancer
- Do pre‐irradiation dental extractions reduce the risk of osteoradionecrosis of the mandible?
- Guidelines Insights: Hepatobiliary Cancers, Version 2.2019
- BRAF-mutated, Microsatellite-stable Adenocarcinoma of the Proximal Colon
- Intensity-Modulated Radiotherapy in the Treatment of Oropharyngeal Cancer: Clinical Outcomes and Patterns of Failure
- HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population
- Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer
- Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma
- Intensity‐modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal
- Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
- Hepatobiliary Cancers, Version 2.2014